De novo malignant tumors following liver transplantation. A single-center experience in Argentina;Tumores malignos de novo en el trasplante hepático experiencia de un centro en la Argentina

Medicina (Argentina)

Volumn 75, Issue 1, 2015, Pages 18-22

  Antinucci, Florencia ^a   Anders, Margarita ^a   Orozco, Federico ^a   Mella, José ^a   Cobos, Manuel ^a   McCormack, Lucas ^a   Mastai, Ricardo ^a  

^a HOSPITAL ALEMÁN   (Argentina)

Author keywords

De novo tumors; Liver transplantation; Neoplasm

Indexed keywords

CORTICOSTEROID; MYCOPHENOLIC ACID; TACROLIMUS; DRUG COMBINATION; IMMUNOSUPPRESSIVE AGENT;

ADENOCARCINOMA; ADULT; ARGENTINA; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE COURSE; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; NON MELANOMA SKIN CANCER; RETROSPECTIVE STUDY; TUMOR DIAGNOSIS; ADVERSE EFFECTS; AGED; COLONIC NEOPLASMS; DRUG COMBINATION; FEMALE; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; PROSTATIC NEOPLASMS; SKIN NEOPLASMS; SURVIVAL;

ADENOCARCINOMA; AGED; ARGENTINA; COLONIC NEOPLASMS; DRUG COMBINATIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84939785615     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Cejas NG, Villamil FG, Lendoire JC, et al. Improved waiting-list outcomes in Argentina after the adoption of a model for end-stage liver disease-based liver allocation policy. Liver Transpl 2013; 19: 711-20.
2. Levy M, Backman L, Husberg B, et al. De novo malignancy following liver transplantation: a single-center study. Transplant Proc 1993; 25: 1397-9.
3. Frezza EE, Fung JJ, van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997; 44: 1172-81.
4. Jiang Y, Villeneuve PJ, Fenton SS, Schaubel DE, Lilly L, Mao Y. Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study. Liver Transpl 2008; 14: 1588-97.
5. Hiesse C, Rieu P, Kriaa F, et al. Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period. Transplant Proc 1997; 29: 831-3.
6. Herrero JI, Lorenzo M, Quiroga J, et al. De novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl 2005; 11: 89-97.
7. Yao FY, Gautam M, Palese C, et al. De novo malignancies following liver transplantation: a case-control study with long-term follow-up. Clin Transplant 2006; 20: 617-23.
8. Penn I. Why do immunosuppressed patients develop cancer? Crit Rev Oncog 1989; 1: 27-52.
9. Penn I. The changing pattern of post-transplant malignancies. Transplant Proc 1991; 23: 1101-3.
10. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897-904.
11. Chandok N, Watt KD. Burden of de novo malignancy in the liver transplant recipient. Liver Transpl 2012; 18: 1277-89.
12. Desai R, Neuberger J. Donor transmitted and de novo cancer after liver transplantation. World J Gastroenterol 2014; 20: 6170-9.
13. Piselli P, Busnach G, Fratino L, et al. De novo malignancies after organ transplantation: focus on viral infections.Curr Mol Med 2013; 13: 1217-27.
14. Herrero JI. De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl 2009; 15: Suppl 2: S90-4.
15. Chak E, Saab S. Risk factors and incidence of de novo malignancy in liver transplant recipients: a systematic review. Liver Int 2010; 30: 1247-58.
16. Penn I. Occurrence of cancers in immuno suppressed organ transplant recipients. ClinTranspl 1998; 147-58.
17. Penn I. Postransplantation de novo tumors in liver allograft recipients. Liver Transpl Surg 1996; 2: 52-9.
18. Di Giovana JJ. Postransplantation skin cancer: scope of the problem, management and role for systemic retinoid chemoprevention. Transplant Proc 1998; 30: 2771-5.
19. Aberg F, Pukkala E, Hockerstedt K, Sankila R, Isoniemi H. Risk of malignant neoplasms after liver transplantation: A population-based study. Liver Transplant 2008; 14: 1428-36.
20. Huttner E, Mathies U, Nikolova T, Ehrenreich H. A follow-up study on chromosomal aberrations in lymphocytes of alcoholics during early, medium and long-term abstinence. Alcohol Clin Exp Res 1999; 23: 344-8.
21. Jerrels TR, Saad AJ, Domiati-Saad R. Effects of ethanol on parameters of immunity and host defense mechanisms to infections agents. Alcohol 1992; 9: 459-63.
22. Castellsague X, Muñoz N, De Stefani E, et al. Smoking and drinking cessation and risk of esophageal cancer (Spain). Cancer Causes Control 2000; 11: 813-8.
23. Jiménez-Romero C, Manrique Municio A, Marqués Medina E, et al. Incidence of de novo nonmelanoma skin tumors after liver transplantation for alcoholic and nonalcoholic liver diseases. Transplant Proc 2006; 38: 2505-7.
24. Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer 2007; 7: 599-612.
25. Preston DS, Stern RS. Nonmelanoma cancers of the skin. N Engl J Med 1992; 327: 1649-52.
26. Barret W, First RM, Aron BS, Penn I. Clinical course of malignancies in renal transplant recipients. Cancer 1993; 72: 2186-9.